Tags

Type your tag names separated by a space and hit enter

Development of dapivirine vaginal ring for HIV prevention.
Antiviral Res. 2013 Dec; 100 Suppl:S3-8.AR

Abstract

In the continuing effort to develop effective HIV prevention methods for women, a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine is currently being tested in two safety and efficacy trials. This paper reviews dapivirine ring's pipeline development process, including efforts to determine safe and effective dosing levels as well as identify delivery platforms with the greatest likelihood of success for correct and consistent use. Dapivirine gel and other formulations were developed and tested in preclinical and clinical studies. Multiple vaginal ring prototypes were also tested, resulting in the current ring design as well as additional designs under consideration for future testing. Efficacy results from clinical trials are expected in 2015. Through ongoing consultations with national regulatory authorities, licensure requirements for dapivirine vaginal ring approval have been defined. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.

Authors+Show Affiliations

International Partnership for Microbicides, Silver Spring, MD, USA. Electronic address: bdevlin@ipmglobal.org.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24188702

Citation

Devlin, Bríd, et al. "Development of Dapivirine Vaginal Ring for HIV Prevention." Antiviral Research, vol. 100 Suppl, 2013, pp. S3-8.
Devlin B, Nuttall J, Wilder S, et al. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100 Suppl:S3-8.
Devlin, B., Nuttall, J., Wilder, S., Woodsong, C., & Rosenberg, Z. (2013). Development of dapivirine vaginal ring for HIV prevention. Antiviral Research, 100 Suppl, S3-8. https://doi.org/10.1016/j.antiviral.2013.09.025
Devlin B, et al. Development of Dapivirine Vaginal Ring for HIV Prevention. Antiviral Res. 2013;100 Suppl:S3-8. PubMed PMID: 24188702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of dapivirine vaginal ring for HIV prevention. AU - Devlin,Bríd, AU - Nuttall,Jeremy, AU - Wilder,Susan, AU - Woodsong,Cynthia, AU - Rosenberg,Zeda, Y1 - 2013/11/01/ PY - 2013/06/03/received PY - 2013/09/03/revised PY - 2013/09/29/accepted PY - 2013/11/6/entrez PY - 2013/11/6/pubmed PY - 2014/7/16/medline KW - Dapivirine KW - HIV prevention KW - Microbicides KW - Vaginal ring SP - S3 EP - 8 JF - Antiviral research JO - Antiviral Res VL - 100 Suppl N2 - In the continuing effort to develop effective HIV prevention methods for women, a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine is currently being tested in two safety and efficacy trials. This paper reviews dapivirine ring's pipeline development process, including efforts to determine safe and effective dosing levels as well as identify delivery platforms with the greatest likelihood of success for correct and consistent use. Dapivirine gel and other formulations were developed and tested in preclinical and clinical studies. Multiple vaginal ring prototypes were also tested, resulting in the current ring design as well as additional designs under consideration for future testing. Efficacy results from clinical trials are expected in 2015. Through ongoing consultations with national regulatory authorities, licensure requirements for dapivirine vaginal ring approval have been defined. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/24188702/Development_of_dapivirine_vaginal_ring_for_HIV_prevention_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(13)00285-4 DB - PRIME DP - Unbound Medicine ER -